First company in North America to undertake a clinical trial of Photobiomodulation (PBM) for Dry AMD.

The Treatment is available “off label” – Results consistent with the TORPA study data.

 

Ocular Coherence Tomography (OCT)

“Live” cross section through the retina resolving to just several microns.

 

Drs Dotson and Dr Merry

ARVO 2016, Seattle

Drs Dotson and Merry presenting clinical outcomes at ARVO 2016 in Seattle.

 

ETDRS Letter change post treatment

Number and percentage of eyes achieving a letter score change immediately post treatment.

 

Photospectra is the first company in Canada and the USA to undertake a clinical trial of Photobiomodulation (PBM) for Dry AMD.

We expect PBM to be a major new treatment for dry AMD patients – safe, effective and affordable when proven in clinical studies. We are dedicated to proving the merits of PBM through ethical, responsible, well designed and well-executed clinical studies.

The TORPA trial was completed and presented at ARVO 2012. Further off label data has been presented internationally at ARVO 2016 in Seattle and Euretina 2016 in Copenhagen. This data has now been published in ACTA Ophthalmologica; a high impact, peer reviewed, international Ophthalmology journal.

LIGHTSITE I, 2017

Adobe_PDF_file_icon_32x32 Click icon to view or right-click to download.

PBM Paper ACTA

Adobe_PDF_file_icon_32x32 Click icon to view or right-click to download.

Dry AMD Presentation

Adobe_PDF_file_icon_32x32 Click icon to view or right-click to download.

WALT NAALT 2014

Adobe_PDF_file_icon_32x32 Click icon to view or right-click to download.

EURETINA 2016, Copenhagen

Adobe_PDF_file_icon_32x32 Click icon to view or right-click to download.

TORPA results

Adobe_PDF_file_icon_32x32 Click icon to view or right-click to download.

TORPA paper

Adobe_PDF_file_icon_32x32 Click icon to view or right-click to download.

Photospectra has noted some very exciting anatomical changes of drusen reduction in association with vision improvement.

Company and Industry News

(More here)

Resignation from LumiThera

Drs. Merry and Dotson resigned from the board of directors of Lumithera Inc. on April 3rd 2017.  Both physicians no longer have an active management role within Lumithera Inc. They both however remain firm believers in the science and clinical application of...

read more

Dr. Merry graduated in Medicine from The Royal London Hospital, U.K. in 1982. He attended 2 years of Ophthalmology Residency training the University of Toronto.

He, along with Dr. Robert Dotson, have been pioneering the clinical application of Photobiomodulation in AMD and hope to provide a simple, non-invasive therapy for this enormous unmet need.

For more on Dr. Merry please read About Us.